AT-1412 is under clinical development by Kling Biotherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AT-1412’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KBA-1412 is under development for the treatment of solid tumors, melanoma. It acts by targeting cells expressing CD9 epitope. It is a fully human monoclonal antibody developed based on AIMSelect and AIMProve platforms. It was also under development for colon cancer, pancreatic cancer , melanoma, solid tumors B-cell acute lymphoblastic leukemia, gastric, breast, esophageal cancer.and multiple myeloma. It is administered through intravenous route.
Kling Biotherapeutics overview
Kling Biotherapeutics (Kling Bio) is a biotherapeutics discovery and development company focusing on novel antibody based therapeutics. Kling Bio is headquartered in Amsterdam, the Netherlands.
For a complete picture of AT-1412’s drug-specific PTSR and LoA scores, buy the report here.